ACIU vs AZN

ACIU's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 1/9 indicates extreme weakness in operational and financial health, while the absence of an Altman Z-Score raises unquantified bankruptcy risk. Despite a strong analyst consensus of 'strong_buy' and a target price of $8.98, the company exhibits catastrophic profitability metrics—negative ROE (-74.63%), gross and net margins at 0%, and a staggering -1671.88% operating margin. Revenue has collapsed by 96.3% YoY, and the stock trades at an absurd Price/Sales of 69.38, far exceeding peer benchmarks. The 52-week range ($1.43–$4.00) and 5-year decline of 62.7% underscore long-term underperformance, despite recent short-term price gains.

AstraZeneca's deterministic health score is concerning with a Piotroski F-Score of 4/9, indicating marginal financial stability. While profitability metrics like ROE (21.67%) and gross margin (83.26%) are strong, the current price of $92.95 trades significantly above the Graham Number of $45.06, reflecting high growth expectations. Revenue and earnings growth are robust (12% and 78% YoY, respectively), but recent earnings surprises have been volatile, including a -25.9% miss in Q3 2025. Analysts maintain a strong_buy recommendation, though insider selling and weak technical trends (10/100) suggest caution near-term.